Shanghai ChemPartner (ChemPartner) has expanded its integrated drug discovery research collaboration with Agios. ChemPartner would provide integrated services in the areas of protein science, HTS, in-vitro enzyme assay, cell biology, and in-vivo pharmacology. They will be used for Agio’s R&D program to discover novel clinical candidates for oncology indications.
Michael Hui, Founder and CEO of ChemPartner, said: ChemPartner is pleased to build upon this existing collaboration and work closely with the experienced scientists at Agios to develop new clinical compounds for oncology indications.”
“The partnership demonstrates the strength and breadth of our integrated drug discovery and development capabilities and this is a wonderful opportunity to share expertise and complement strengths, he added.